Ionis, Cyclerion tout positive data readouts; MAIA prices first biotech IPO in over two months
Ionis put out positive topline results from a Phase IIb trial on end-stage renal disease, investigating patients on dialysis.
The drug candidate, fesomersen, achieved its primary goal of “no increase in incidence of major bleeding and clinically relevant non-major bleeding,” compared to placebo. The study, named RE-THINC ESRD, was conducted by Bayer, which licensed the drug from Ionis.
Specific data will be presented at a later date at an undisclosed, upcoming medical meeting.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.